
MSM is a popular choice for dog joint health, but the science is limited, and no veterinary studies exist yet.
Published in
Natural IngredientsMSM is appearing more and more often in supplements designed for canine joint comfort. Yet behind this recent popularity lies a little-known reality: MSM remains one of the least scientifically documented ingredients in veterinary medicine.
So, what exactly is MSM? Can it really support the mobility of a dog that is starting to show signs of stiffness? And what do scientific studies say?
This article provides a transparent overview backed by evidence.
MSM, or methylsulfonylmethane, is a small molecule naturally present in the environment and in certain animal tissues. Chemically speaking, it is an organosulphur compound, meaning an organic molecule that contains sulphur.
Sulphur is an essential mineral for mammals. It is found in many tissues, including cartilage, tendons, ligaments, skin and hair, as well as in certain amino acids involved in cellular function.
Organosulphur compounds are molecules derived from living organisms that contain a sulphur atom in their structure. This sulphur participates in chemical bonds called "disulphide bridges". These bridges play an important role in protein stability, particularly in proteins that make up connective tissues such as collagen and certain components of the cartilage matrix.
In other words, MSM provides a form of sulphur that the body can readily use.
Sulphur is involved in the production or stability of several key components:
This is why MSM is sometimes highlighted in joint supplements: it provides an essential element used by several joint structures.
In supplements, MSM most often comes in the form of purified crystalline powder (generally at 99.9%), sometimes in capsules for humans. It is taken orally, mixed into food or diluted in water.
For dogs, there are products containing MSM alone or combined with other joint ingredients. They come as powder, tablets or soft chews. However, no optimal dose has been determined in dogs, due to a lack of clinical studies, and current recommendations are based mainly on extrapolations from human nutrition.
The proposed mechanisms of MSM come mainly from laboratory studies on cells or studies in species other than dogs. They help explain its theoretical relevance, but do not prove its clinical efficacy.
Much of joint discomfort is linked to local inflammation. In several in vitro studies, MSM appears to reduce the activity of certain inflammatory mediators such as:
In other words, this research suggests that MSM may limit the activation of these inflammatory pathways.
However, it is important to note that these observations have never been confirmed in dog joints.
The joint naturally produces free radicals, unstable molecules that, in excess, contribute to cartilage wear. At high concentrations, these free radicals can damage cartilage cells, alter the extracellular matrix, and sustain inflammation.
In several experimental models, MSM has been shown to stimulate the activity of antioxidant enzymes such as superoxide dismutase (SOD) and to reduce certain markers of cellular oxidation.
These results suggest that it could play a protective role against oxidative stress, even if this has not been demonstrated in dogs.
Cartilage and the tissues surrounding the joint rely on molecules that require sulphur for their production, including:
By providing a readily assimilable source of sulphur, MSM could theoretically help maintain these cartilaginous structures.
However, no study has shown that this intake translates into improved mobility or joint comfort in dogs.
Since there is no study on MSM in dogs, we must look at what has been done in humans and in animal models. Studies are few in number and their results show modest effects.
The first data come from a randomised trial conducted by Kim et al. (2006) in 50 adults with knee osteoarthritis. Participants received 3.375 g/day of MSM or a placebo for twelve weeks. Pain scores (WOMAC) showed a statistically significant improvement in pain and function, but the effect was small, limiting its clinical relevance. In short, the improvement was statistically significant but too small to represent a major clinical benefit.
A more robust study conducted by Debbi et al. (2011) in 100 patients with osteoarthritis reached similar conclusions. After twelve weeks of supplementation at 6 g/day, pain and function improved modestly, but blood inflammation markers such as cytokines remained unchanged. The study notes that the observed benefits were 'of low magnitude' and had uncertain clinical relevance.
The observed improvements are modest and their clinical relevance remains uncertain.
More recently, Toguchi et al. (2023) evaluated 2 g/day of MSM in 88 adults with mild knee pain. The pain score (JKOM) improved significantly, but again inflammatory biomarkers (IL-1β and IL-6) showed no notable change. The observed effect remained largely subjective and moderate.
Trials generally report good tolerability over 8 to 12 weeks, with no abnormalities in blood or urine tests. Reported adverse effects include digestive issues such as bloating and mild diarrhoea, as well as occasional headaches.
To date, there is no clinical study evaluating MSM in dogs in the context of joint disorders.
No randomised trial, no dose-ranging study, and no pain or mobility measurement has been published in veterinary medicine. The proposed mechanisms and results observed in humans or animal models therefore cannot be reliably extrapolated to dogs.
In the current state of knowledge, the actual efficacy of MSM on mobility or joint comfort in dogs remains unknown.
In the absence of studies conducted in dogs, it is difficult to recommend MSM as a reliable solution for joint comfort. Research in humans shows a real but modest effect, and animal models provide only theoretical leads, sometimes observed at very high doses that would not be transferable to a companion animal.
This does not mean that MSM is dangerous: available data suggest good short-term tolerability, mainly with some digestive issues reported in humans. But due to a lack of veterinary trials, its actual benefit for mobility, pain or quality of life in dogs remains unknown.
In practice, MSM can be considered a secondary supplement, but it should not replace approaches whose efficacy has been demonstrated in dogs: weight management, appropriate physical activity, a balanced diet and better-documented supplements such as omega-3 EPA and DHA or green-lipped mussel oil.
Discover our comparison of joint supplements for dogs
In summary, MSM can be integrated into an overall strategy, but its efficacy on joint disorders in dogs has not been demonstrated. Any use should be discussed with a veterinarian, especially if the dog has established pain, persistent lameness or ongoing medical treatment.
MSM is often presented as a complementary treatment, but the evidence remains limited. Human studies show a real but modest effect, and no clinical work has been conducted in dogs. Based on current knowledge, MSM can be considered a secondary supplement, but it should not replace solutions whose efficacy has been demonstrated in veterinary medicine, such as omega-3 or green-lipped mussel oil. Any decision regarding its use should be individualised and discussed with a veterinarian.
This article was written by the R&D team at Laboratoire Sensilia, experts in animal nutrition.
Sensilia Laboratory is a French, family-owned and independent laboratory based in Gironde, France. Since 2019, we have been researching and manufacturing healthy, innovative wellness products.